Considering the protective effect that Gal-1 exerts on cancer cells against the action of the immune system through its deleterious effect on activated T-cells and the activation of oncogenic H-Ras proteins, the ways to reduce its expression to increase the efficiency of T-cell mediated immunotherapy in patients with HNSCC have also been evaluated [9,26,31]. This evidence concerns the gene HRAS and head and neck squamous cell carcinoma.